About this Video

• Video Title: The End Of Steroids? NEW Muscle Drugs Are Here
• Channel: Renaissance Periodization
• Speakers: Dr. Mike, Scott
• Duration: 00:26:39

Introduction

This video discusses a new class of muscle-building drugs, non-androgenic anabolics, developed by Regeneron Pharmaceuticals. The speakers analyze a study on these drugs using non-human primates, highlighting their potential to surpass steroids in muscle growth while minimizing side effects.

Key Takeaways

1. Non-androgenic Anabolics Show Promise: A study using non-human primates demonstrated significant fat loss and muscle gain using a combination drug therapy (travagramab and gerretmab), which targets myostatin and actin.
2. Superior to Steroids and Weight Loss Drugs: The combination drug therapy resulted in substantially greater fat loss than dieting alone, simaglutide (a weight-loss drug), or a myostatin blocker alone, with minimal muscle loss. In some cases, muscle gain was observed even during a caloric deficit.
3. Significant Muscle Growth Potential: The study suggests that these drugs could enable unprecedented muscle growth in humans, potentially exceeding the effects of high-dose steroids without the associated side effects.
4. Aesthetic Benefits: The drugs' ability to selectively target muscle growth could allow for more aesthetic physique development, even potentially increasing muscles not directly trained.
5. Impending Market Disruption: The presenters predict that these drugs will revolutionize the fitness and bodybuilding industries, potentially leading to reduced steroid use and a renewed focus on targeted muscle development. They anticipate multiple competitors entering the market soon.

Based on the video, the presenters suggest that the primary side effect of the new muscle-building drugs might be increased hunger and a need for higher protein intake due to the radical increase in muscle mass. They mention that this could be mitigated by using a weight-loss drug like semaglutide to offset the increased appetite. The primate study showed minimal other side effects, unlike the significant androgenic side effects associated with steroids. The presenters explicitly state that the drugs, as studied, exhibited "zero androgenic side effects."